Dexamethasone to Treat Oral Lichen Planus
Oral Lichen Planus
About this trial
This is an interventional treatment trial for Oral Lichen Planus focused on measuring Mucosal Disease, Topical Steroids, Salivary Diagnostics, Oral Pain, Quality of Life Indicators, Oral Lichen Planus
Eligibility Criteria
INCLUSION CRITERIA: Biopsy confirmed symptomatic oral lichen planus. World Health Organization histological criteria (12) in combination with a compatible clinical appearance will be used for diagnosis. No current treatment with immunomodulatory agents. A one-month washout period will be required prior to enrollment if patients are taking immunomodulatory agents. Prior treatment with topical steroids will be allowed provided the presence of symptomatic lesions. Age greater than 12 years old. Lichen planus is very rare in patients younger than 40 years old. Patients must rinse and spit the medication rather than swallow it. Oral rinses such as topical fluorides are not recommended for young children. Patients of both sexes and all racial and ethnic groups will be eligible. Symptomatic lichen planus with a score of at least 35 mm on a visual analog scale for pain. Oral lichen planus score of at least 3 on the lichen planus severity scale. EXCLUSION CRITERIA: Unable to undergo oral biopsy for diagnosis. Asymptomatic lichen planus with no ulcerated or erythematous oral lesions. Treatment with immunomodulatory agents within 1 month of the randomization. Hepatitis C infection. Documented hypersensitivity to dexamethasone. Pregnancy or lactation. Poorly controlled diabetes. Inability or unwillingness to give written informed consent.
Sites / Locations
- National Institute of Dental And Craniofacial Research (NIDCR)